期刊文献+

特利加压素治疗肝肾综合征的疗效分析 被引量:3

Observation of terlipressin in management of patients with hepatorenal syndrome
下载PDF
导出
摘要 目的:观察特利加压素治疗肝肾综合征的疗效。方法:60例患者分为2组,在内科综合治疗基础上,A组使用特利加压素,B组为对照组,观察患者临床表现、实验室指标、转归等。结果:A组较B组平均动脉压增高、尿量增多、血Cr降低,有效率增加,差异有统计学意义。结论:特利加压素对肝肾综合征的治疗安全、有效。 AIM:To observe the effect of terlipressin in the management of patients with hepatorenal syndrome.METHODS:60 patients were divided into two groups.In Group A,terlipressine was used and Group B was control group.The clinical manifestation,laboratory examination,turnover were observed during treatment.RESULTS:Compared with Group B,the effective power,the mean arterial pressure and the total urine output were increased significantly,the serum creatinine level was decreased remarkably.CONCLUSION:Terlipressin is safe and effective on hepatorenal syndrome with minute adverse reaction.
出处 《中国临床药理学与治疗学》 CAS CSCD 2009年第10期1164-1167,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 肝肾综合征 特利加压素 血管活性药物 药物治疗 hepatorenal syndrome tterlipressin vasoactive agent pharmacotherapy
  • 相关文献

参考文献9

  • 1李晓鸥,朱元东,娄国强.血管活性物质的分布与肝肾综合征的发病机制[J].国际流行病学传染病学杂志,2006,33(4):258-260. 被引量:1
  • 2Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis [ J ]. Gut, 2006,55 ( Supple VI ) : Vi1 - 12.
  • 3Biswas KD, Jain AK. Hepatorenal syndrome [ J ]. Trop Gastroenterol, 2002,23 : 113 - 116.
  • 4Esrailian E, Pantangco ER, Kyulo NL, et al. Octreotide/Midodrine therapy significantly improves renal function and 30- day survival in patients with type 1 hepatorenal syndrome[J]. Dig Dis Sci, 2007,52(3) :742 - 748.
  • 5Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study[ J]. Hepatology, 2002,36(4) : 941 - 948.
  • 6Danalioglu A, Cakaloglu Y, Karaca C, et al. Terlipressin and albumin combination treatment in hepatorenal syndrome[ J ]. Hepatogastroenterology, 2003,50 ( Suppl 2 ) :ccciii-cccv.
  • 7Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study[ J]. Gastroenterology, 2008,134(15) : 1352 - 1359.
  • 8Di Micoli A, Bracci E, Cappa FM, et al. Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome [ J ]. Dig Liver Dis, 2008,40 (4) :304 - 305.
  • 9Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation [ J ]. Hepatology, 2005,41(6) : 1282- 1289.

二级参考文献27

  • 1Wong F,Blendis L.New Challenge of Hepatorenal Syndrome:Prevention and Treatment.Hepatology,2001,34(6):1242-1251.
  • 2Arroyo V,Gines P,Gerbes AL,et al.Definitions and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.Hepatology,1996,23(1); 164-176.
  • 3Bataller R,Gines P,Arroyo V,et al.Hepatorenal syndrome.Clin liver Dis,2002,20(2):487-507.
  • 4Moore K.The hepatorenal syndrome.Clin Sci(Lond),1997,92(5):433-443.
  • 5Cardenas A,Uriz J,Gines P,et al.Hepatorenal syndrome.Liver Transpl,2000,6(4 Suppl 1):S63-S71.
  • 6Bataller R,Sort P,Gines P,et al.Hepatorenal syndrome:definition,pathophysiology,clinical features and management.Kidney Int Suppl,1998,66:S47-S53.
  • 7Nijveldt RJ,Teerlink T,Siroen MP,et al.The liver is an important organ for elimination of asymmetric dimethylarginine(ADMA).Hepatology,2002,4:175-177.
  • 8Liu SL,Huang JH,Rockey DC.The role of AKT in sinusoidal endothelial cell production of nitric oxide:implications for the pathogenesis of portal hypertension.Hepatology,2002,4:229-231.
  • 9Merta M,Reiterova J,Rysava R,et al.Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease.Physiol Res,2003,52(4):433-437.
  • 10Rockey D.The cellular pathogenesis of portal hypertension:stellate cell contractility,endothelin and nitric oxide.Hepatology,1997,25(1):2-5.

同被引文献24

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部